Candel Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
The following table describes contracts, instructions or written plans for the sale or purchase of our securities adopted by our directors and certain officers during the three months ended March 31, 2026, each of which is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c), referred to as Rule 10b5-1 trading plans.
| Name | Action Taken | Nature of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|
| Paul Peter Tak, M.D., Ph.D., FMedSci (Chief Executive Officer, President and Director) | Adoption (March 13, 2026) | Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) | Earlier of (i) June 30, 2027 and (ii) the completed sale of the maximum aggregate number of securities under the plan | Up to 880,245 shares |
| Charles Schoch (Chief Financial Officer, Treasurer and Secretary) | Adoption (March 13, 2026) | Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) | Earlier of (i) June 30, 2028 and (ii) the completed sale of the maximum aggregate number of securities under the plan | Up to 38,038 shares |
| Francesca Barone, M.D., Ph.D. (Chief Scientific Officer) | Adoption (March 16, 2026) | Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) | Earlier of (i) June 30, 2028 and (ii) the completed sale of the maximum aggregate number of securities under the plan | Up to 93,789 shares |
| W. Garrett Nichols, M.D., M.S. (Chief Medical Officer) | Adoption (March 16, 2026) | Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) | Earlier of (i) November 1, 2027 and (ii) the completed sale of the maximum aggregate number of securities under the plan | Up to 52,493 shares |
| Seshu Tyagarajan, Ph.D., RAC (Chief Technical and Development Director) | Adoption (March 16, 2026) | Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) | Earlier of (i) March 31, 2028 and (ii) the completed sale of the maximum aggregate number of securities under the plan | Up to 128,564 shares |
No other directors or officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted, modified and/orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the three months ended March 31, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.